億勝生物科技(01061.HK)擬9700萬元向百盛藥業收購產品權益
格隆匯6月9日丨億勝生物科技(01061.HK)宣佈,於2021年6月9日,公司間接全資附屬珠海億勝與百盛藥業就可能收購事項訂立產品權益轉讓協議。根據產品權益轉讓協議,可能收購事項的代價為人民幣9700萬元。
根據協議,珠海億勝同意收購,而百盛藥業同意轉讓並促使其他相關方轉讓予珠海億勝(及╱或其代名人)與產品(即適麗順)有關的目標資產,其中包括相關知識產權、技術及工藝,以及其他有關權益(包括合約權益)及其MAH。
此前公佈,目標資產指就產品而言,百盛藥業及╱或其他有關各方持有的(i)所有與其相關的知識產權、所有與其產品研發及生產有關的技術及工藝(包括製造產品所用原材料的有關知識產權及權益以及(如適用)其的有關MAH及其他權益),以及所有與產品有關的其他權益(包括合約權益及與產品有關或基於產品相關內容的進一步研發可能產生的知識產權及任何其他權益);及(ii)其的藥品上市許可人,許可人於收到國家藥監局授予的藥品註冊證後獲得的許可,其允許許可人與合約製造機構合作製造相關藥品(MAH)。
公吿稱,產品(即適麗順)已於2010年獲得批准,可用於治療中心性漿液性脈絡膜視網膜病變、中心性滲出性脈絡膜視網膜病變、玻璃體出血、玻璃體混濁及視網膜中央靜脈阻塞等。億勝醫藥(公司之間接全資附屬公司)已獲委任為獨家代理,以根據代理協議在中國授權地區進行適麗順分銷及營銷。預期可能收購事項將使集團能夠實行進一步的臨牀開發計劃,並進一步投資於產品營銷及擴大銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.